Technology group OMESTI Berhad has increased its investment in the Bemed Group of companies with the acquisition of a 70 percent shareholding in each of nine additional Bemed pharmaceutical businesses. The investment represents a total cash consideration of RM15.8 million. The Bemed companies that form part of the latest acquisition are engaged in various activities, including trading and retail sale of pharmaceutical products, orthopaedic and medical goods, perfumery products, cosmetics and toiletries. Earlier this year, OMESTI acquired a 70% shareholding in licensed healthcare provider Bemed Tempua Sdn Bhd, which holds a Master Sales & Distribution Agreement for the Sinovac COVID-19 vaccine with Pharmaniaga LifeScience Sdn Bhd.
Gerard Monteiro, Executive Director of OMESTI Berhad, says,
“Our initial investment in the Bemed Group enabled us to launch our Vaccin8 Programme as part of the nationwide immunisation drive to combat COVID-19. The Programme has since provided vaccination services to companies across the country and has been instrumental in helping these businesses return to full operations as the economy emerges from successive MCO (Movement Control Order) lockdowns. As we are all aware, COVID-19 is still very prevalent in our communities. We are now gearing up to provide booster vaccinations to these companies to help them ensure maximum protection for their workforce.”
Clients to date have included Malaysian companies and conglomerates from the plantation, agriculture, fisheries, manufacturing, construction and hospitality sectors, as well as engineering, oil & gas and others.
“This additional investment in the Bemed Group will enable us to further expand our portfolio of healthcare services and our customer base. Equally, we will be deploying our technology expertise to fully digitise the operations of our healthcare offering, putting the patient and consumer at the heart of our ecosystem. This digital ecosystem, which will be rolled out in phases, will span the entire medical requirements chain of the individual," he adds.
Services will range from initial e-consultation with medical professionals to diagnosis, through to prescription issue and fulfilment, follow-up consultation and purchase of general medical supplies via the Group’s online pharmacy portal.
COVID-19 Antigen Rapid Test Kits are also part of the OMESTI Healthcare inventory. The oral fluid ProDetectTM kits, which are made in Malaysia by Mediven® [Medical Innovation Ventures Sdn Bhd], deliver high reliability and accuracy and are able to detect Delta and other variants of concern.
The OMESTI Healthcare Group has built up a substantial network of medical partners across the country, comprising doctors and clinics, who are serving the communities where they operate to provide vaccinations and on-site screening services. This allows for mass-testing of employees in a safe, secure environment, helping to identify any infection early on and contain any possible spread. As more restrictions are lifted with hospitality venues opening and events being allowed, the Group is also offering screening services for corporate events. Pre-entry testing is conducted at such events, enabling companies to ensure a safe, COVID-19-free experience for their clients.